IMVT
NASDAQImmunovant Inc.
Price$43.51-0.72 (-1.63%)
01:30 PM07:45 PM
News · 26 weeks54-60%
2026-03-012026-08-23
Mix2690d
- Insider16(62%)
- SEC Filings8(31%)
- Earnings2(8%)
Latest news
25 items- INSIDERChief Operating Officer Gloria Melanie sold $134,953 worth of shares (3,056 units at $44.16), decreasing direct ownership by 1% to 219,301 units (SEC Form 4) (withholding tax)4 - Immunovant, Inc. (0001764013) (Issuer)
- SECSEC Form 10-Q filed by Immunovant Inc.10-Q - Immunovant, Inc. (0001764013) (Filer)
- SECImmunovant Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - Immunovant, Inc. (0001764013) (Filer)
- PRImmunovant Provides Corporate Updates and Reports Financial Results for the Quarter Ended June 30, 2026All IMVT-1402 clinical development timelines remain on track, including ongoing studies in Graves’ disease (GD), myasthenia gravis (MG), chronic inflammatory demyelinating polyneuropathy (CIDP), difficult-to-treat rheumatoid arthritis (D2T RA), Sjögren’s disease (SjD) and cutaneous lupus erythematosus (CLE)Current cash balance provides runway to the potential launch of IMVT-1402 in GDRoivant will host a live conference call and webcast at 8:00 a.m. ET on Thursday, August 6, 2026 DURHAM, N.C., Aug. 06, 2026 (GLOBE NEWSWIRE) -- Immunovant (NASDAQ:IMVT), a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases, today reported corporate update
- INSIDERDirector Pande Atul exercised 1,500 shares at a strike of $8.43 and sold $59,700 worth of shares (1,500 units at $39.80) as part of a pre-agreed trading plan (SEC Form 4)4 - Immunovant, Inc. (0001764013) (Issuer)
- INSIDERChief Financial Officer Girao Tiago sold $263,015 worth of shares (6,798 units at $38.69), decreasing direct ownership by 3% to 240,798 units (SEC Form 4) (for withholding tax)4 - Immunovant, Inc. (0001764013) (Issuer)
- INSIDERChief Technology Officer Stout Jay S sold $110,537 worth of shares (2,857 units at $38.69), decreasing direct ownership by 1% to 205,341 units (SEC Form 4) (for withholding tax)4 - Immunovant, Inc. (0001764013) (Issuer)
- PRImmunovant to Report Financial Results for the First Quarter Ended June 30, 2026, and Provide Business Update on Thursday, August 6, 2026DURHAM, N.C., July 23, 2026 (GLOBE NEWSWIRE) -- Immunovant, Inc. (Nasdaq: IMVT) today announced that it will report its financial results for the first quarter ended June 30, 2026 on Thursday, August 6, 2026 before the market opens. Roivant Sciences Ltd. (ROIV), Immunovant’s majority stockholder, will host a live conference call and webcast at 8:00 a.m. ET that same day, which will include a business update for Immunovant. To access the Roivant (NASDAQ:ROIV) conference call by phone, please register online using this registration link. The presentation and webcast details will also be available under "News & Events" in the Investors section of the Immunovant website at https://www.immunov
- SECSEC Form DEFA14A filed by Immunovant Inc.DEFA14A - Immunovant, Inc. (0001764013) (Filer)
- SECSEC Form DEF 14A filed by Immunovant Inc.DEF 14A - Immunovant, Inc. (0001764013) (Filer)
- INSIDERChief Operating Officer Gloria Melanie sold $80,532 worth of shares (2,036 units at $39.55), decreasing direct ownership by 0.91% to 222,357 units (SEC Form 4) to satisfy withholding tax4 - Immunovant, Inc. (0001764013) (Issuer)
- INSIDERChief Legal Officer Van Tuyl Christopher sold $47,702 worth of shares (1,206 units at $39.55), decreasing direct ownership by 0.67% to 179,391 units (SEC Form 4) to satisfy withholding tax4 - Immunovant, Inc. (0001764013) (Issuer)
- INSIDERChief Technology Officer Stout Jay S sold $137,925 worth of shares (3,487 units at $39.55), decreasing direct ownership by 2% to 208,198 units (SEC Form 4) (tax withholding)4 - Immunovant, Inc. (0001764013) (Issuer)
- INSIDERChief Executive Officer Venker Eric sold $118,980 worth of shares (3,092 units at $38.48), exercised 92,188 shares at a strike of $14.46 and returned $3,304,030 worth of shares to the company (86,629 units at $38.14), increasing direct ownership by 0.98% to 254,280 units (SEC Form 4) (withholding obligation)4 - Immunovant, Inc. (0001764013) (Issuer)
- INSIDERChief Operating Officer Gloria Melanie sold $678,604 worth of shares (17,714 units at $38.31), decreasing direct ownership by 7% to 224,393 units (SEC Form 4)4 - Immunovant, Inc. (0001764013) (Issuer)
- INSIDERChief Technology Officer Stout Jay S sold $1,532,309 worth of shares (40,000 units at $38.31), decreasing direct ownership by 16% to 211,685 units (SEC Form 4)4 - Immunovant, Inc. (0001764013) (Issuer)
- INSIDERChief Legal Officer Van Tuyl Christopher exercised 17,824 shares at a strike of $15.20 and sold $682,887 worth of shares (17,824 units at $38.31) (SEC Form 4)4 - Immunovant, Inc. (0001764013) (Issuer)
- INSIDERChief Financial Officer Girao Tiago exercised 10,000 shares at a strike of $15.90 and sold $384,600 worth of shares (10,000 units at $38.46) (SEC Form 4)4 - Immunovant, Inc. (0001764013) (Issuer)
- INSIDERDirector Pande Atul exercised 1,500 shares at a strike of $8.43 and sold $57,015 worth of shares (1,500 units at $38.01) as part of a pre-agreed trading plan (SEC Form 4)4 - Immunovant, Inc. (0001764013) (Issuer)
- SECSEC Form 144 filed by Immunovant Inc.144 - Immunovant, Inc. (0001764013) (Subject)
- SECSEC Form 144 filed by Immunovant Inc.144 - Immunovant, Inc. (0001764013) (Subject)
- INSIDERChief Legal Officer Van Tuyl Christopher sold $93,217 worth of shares (2,634 units at $35.39), decreasing direct ownership by 1% to 180,597 units (SEC Form 4) to satisfy tax liability4 - Immunovant, Inc. (0001764013) (Issuer)
- INSIDERDirector Pande Atul sold $51,030 worth of shares (1,500 units at $34.02) as part of a pre-agreed trading plan and exercised 1,500 shares at a strike of $8.43 (SEC Form 4)4 - Immunovant, Inc. (0001764013) (Issuer)
- SECSEC Form 144 filed by Immunovant Inc.144 - Immunovant, Inc. (0001764013) (Subject)
- INSIDERDirector Fromkin Andrew J. exercised 196,601 shares at a strike of $8.22 and sold $7,438,111 worth of shares (221,951 units at $33.51), decreasing direct ownership by 25% to 74,382 units (SEC Form 4)4 - Immunovant, Inc. (0001764013) (Issuer)
IMVT FAQ
7 questionsWhat does Immunovant Inc. do?
Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops IMVT-1401, a novel fully human monoclonal antibody that selectively binds to and inhibits the neonatal fragment crystallizable receptor, which is in Phase IIa clinical trials for the treatment of myasthenia gravis and thyroid eye disease, as well as has completed initiation of Phase II clinical trials for the treatment of warm autoimmune hemolytic anemia. The company is headquartered in New York, New York. Immunovant, Inc. is a subsidiary of...Where does IMVT stock trade?
Immunovant Inc. (IMVT) is listed on NASDAQ.What sector and industry is IMVT in?
Immunovant Inc. operates in the Health Care sector, Biotechnology: Biological Products (No Diagnostic Substances) industry.When did Immunovant Inc. go public?
Immunovant Inc. (IMVT) completed its IPO in 2019.What are analysts saying about IMVT?
Immunovant Inc. has had 8 recent analyst actions on file. The most recent action was from Bernstein: Mkt Perform with a $2800.00 price target on 2026-03-20. Recent price targets range from $1600.00 to $3600.00.What companies are similar to IMVT?
Notable peers in the same industry include AMGN (Amgen Inc.), GILD (Gilead Sciences Inc.), MRNA (Moderna Inc.), ARGX (argenx SE), RVMD (Revolution Medicines Inc.). Compare IMVT side-by-side with any of them on Quantisnow.How can I track IMVT on Quantisnow?
Quantisnow aggregates Immunovant Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow IMVT to receive live email and push alerts on every new disclosure.